updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
sinc spin baxter
demonstr know stick knit tissu heart
valv edward remain domin forc surgic heart
valv minim invas valv therapi -- one hottest
area cardiac devic
edward done good job refocus higher-margin
product churn meaning innov effort
result impress gross margin
improv sinc becom stand-alon compani although
firm significantli smaller close competitor
abbott term sale remain global leader core
busi tissu heart valv command
global market firm maintain leadership posit
critical-car monitor equip complement heart valv
edward regularli engag serial acquisit
firm recent made seri purchas transcathet mitral
valv technolog order get jump next wave
innov firm remain lead edg domin
balloon-expand sapien transcateth aortic valv also
lead develop transcathet mitral repair replac
product includ pascal cardioband edward pois
ride wave new technolog shift valv replac
transcathet approach especi clinic data
support efficaci safeti product
said still anticip potenti bump
road edward alreadi taken shot transcathet mitral
valv littl success challeng area given
heterogen condit econom behind
transcathet aortic valv replac remain less attract
surgic valv mani hospit though eas
market also becom crowd
abbott fray nonetheless think
long-term clinic trend shift toward transcathet
technolog edward sit pretti
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
spun design
manufactur market rang medic devic equip
advanc stage heart diseas key product includ surgic tissu
heart valv transcathet valv technolog surgic clip cathet
retractor monitor system use measur patient heart
function surgeri firm deriv total sale
outsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
perform track along full-year
project havent made chang
estim boost fair valu
estim bake optimist estim
long-term growth cash flow realiz sinc last
updat see littl chang view edward narrow
econom moat howev think worth monitor
firm stabl moat trend next month
pivot trial transcathet mitral tricuspid
get closer fruition preliminari clinic data favor
european adopt pascal cardioband robust
pleas hear transcathet aortic sapien
valv sale seem grow line procedur growth
second quarter shift saw
last year appear aggress
price corevalv edward indic lost
market share remain disciplin premium
price quarterli sapien revenu sale
respect underli basi see
littl evid rival control
launch lotu edg tavr slow sapien growth
nonetheless wouldnt surpris see practition
tri lotu next quarter boston ramp
physician train establish center
item caught attent quarter first
launch pascal europ run smoothli
cardioband suppli improv two tmtt
product first edward gate european
adopt give us sens devic might
perform sale remain small million
second quarter expect acceler edward
cardiologist train new center establish
next month particularli interest pascal
consid rival abbott recent success mitraclip
saw growth second quarter edward
expect begin enrol pivot pascal trial
function mitral regurgit end year
market
though cardioband struggl manufactur
challeng constrain suppli edward
shift manufactur site improv
situat unlik pascal cardioband first
new direct annuloplasti devic enter market
demonstr strong eas use think could hold
potenti pascal could provid
durabl repair annulu especi function mitral
condit put particular stress anatomi mitral
earliest
boston roll-out
met
enthusiasm still take time put dent sapien
growth view lotu edg current indic
inoper high surgic risk patient sapien
alreadi expand indic includ intermedi
risk pool expect expans encompass
low surgic risk patient second half boston
meanwhil still enrol trial intermedi risk
discontinu self-expand centera tavr product
market europ stop develop
forma devic tricuspid diseas order focu
resourc pascal sapien mitral use
cardioband although medic technolog busi
often one enough shot goal seem
edward shot goal perhap exceed firm
bandwidth success develop commerci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
reflect anticip
expans includ low-risk patient base
consist favor clinic data come edward
trial among group patient
addit intermediate- low-risk patient would
expand patient pool roughli
importantli think edward eventu captur
subseg high-risk surgic patient
intermediate-risk patient low-risk patient
base avail clinic data expect oper
margin hold steadi around effici
gener off-set price pressur competitor enter
market edward balanc invest
support burgeon transcathet mitral tricuspid
technolog pipelin expect sapien growth
recent strength
next-gener launch new clinic data could sway
practition toward sapien entranc new
competitor
account
transcathet aortic mitral tricuspid valv
franchis drive averag annual top-lin growth
edward slightli higher
previous assum
domest price pressur exacerb
expect new entrant emerg may need revisit
assumpt year total think
increas
compound annual
incom
base rel narrow concentr product
portfolio edward rate firm uncertainti high
recogn may substanti upsid patient
pool tavr expand includ intermediate-
way enviabl problem
nevertheless look favor manag decis
alloc resourc deliber support strongest
candid potenti underscor
make apolog make concentr bet
differenti superior technolog back
appropri resourc
boost fair valu estim per share
rais long-term expect
stronger growth account cash flow realiz
sinc last updat europ clear pascal
mitral repair cardioband mitral tricuspid use
project tmtt portfolio reach million
revenu driven product assum
regulatori clearanc
 food drug
administr probabl evoqu
transcathet mitral replac devic approv
tavr remain largest driver valuat
assum low midteen growth sapien revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
competitor falter
low-risk patient addit competit europ remain
peripher
develop
transcathet mitral tricuspid devic case
sketch bull scenario abbott boston
unabl grow major tavr rival
unabl address heart-rhythm complic associ
corevalv condit would drive tavr sale
roughli billion oper margin would
hover averag annual revenu
growth adjust earn growth
scenario bring fair valu estim per
hand see share loss abbott
boston scientif along
aggress price pressur -- expect growth
transcathet aortic valv sale also assum
evoqu never receiv regulatori approv
oper margin peak assumpt
would see top-lin growth price pressur
requir invest research develop
would keep earn growth averag would
slice valuat per share
despit compet rather matur surgic heart valv
market come domin tissu
valv introduct key transcathet aortic valv
technolog sinc grown billion global
market thu dig narrow moat base intang
asset compani long histori pioneer new
heart valv still highli regard cardiac surgeon
technolog advanc edward compet
abbott primarili mechan heart valv
boston scientif howev edward remain heavi
hitter tissu valv segment like mani devic
compani edward compet basi technolog
innov intellectu properti close relationship
physician
last decad edward focus
technolog given heart valv market jolt
develop minim invas aortic heart valv
instal cathet therebi make
procedur recoveri much easier patient current
tradit valv requir extens surgic procedur
implant mean estim half one third
elderli patient need valv replac
frail high-risk undergo surgic valv replac
believ edward bolster leadership posit
tissu heart valv sapien transcathet aortic valv
franchis tavr deliv either
femor arteri similar angioplasti small
hole two rib minim invas therapi
would potenti tap estim american
patient current
inoper high-risk
candid tradit valv surgeri technolog
wide adopt patient pool expand
includ intermediate-risk patient time trial
data amass new low-risk indic expect
anticip firm expand tavr
indic fuel growth
edward also firmli set sight tackl larger
technic challeng develop transcathet mitral valv
repair replac option estim moati
tmv market could grow billion thank
greater incid mitral valv diseas edward
work least four differ repair replac
platform firm recent receiv european
regulatori clearanc two transcathet mitral
stand behind stabl moat trend rate
edward expect continu technolog innov
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
help counter grow threat competit
edward global leader surgic tissu heart valv
less invas technolog put ahead
competitor similar lead edward enjoy
pioneer tavr product think edward may also carv
similar head start impress pipelin
transcathet mitral repair replac product
addit edward alreadi launch next-gener
sapien ultra edward consist improv upon
transcathet product enhanc make
even thinner easier faster use virtual
elimin sever valve-leakag complic
affect patient earlier technolog
compani success develop transcathet
mitral valv technolog think edward could
transcathet valv
everywher formid competitor
key geographi includ abbott
boston scientif present europ boston recent
launch lotu edg valv abbott
also enter next year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oedward effort focu effici higher-
margin product paid gross margin
increas
ocardiothorac surgeon fairli conserv
bunch like stick proven devic brand
pioneer heart valv edward continu
seen gold standard
oedward benefit age popul
experi problem heart valv
congest heart failur greater frequenc
oedward ambit diversifi
minim
invas medic technolog place firm direct
competit much larger competitor
abbott easili bid price
emerg technolog edward
ocompetit abbott like
enter market start time
oif sapien price remain high even entranc
new rival payer may limit usag transcathet
valv intermediate-risk low-risk patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
resourc
edward light debt leverag larg cash invest
posit give firm financi flexibl end
decemb edward major debt outstand
consist roughli million senior unsecur note
matur mean time firm sat
million cash invest follow
recent cardiaq valtech acquisit bolster
mitral valv pipelin gross debt/ebitda stood well
time interest coverag time
view share repurchas like use
manag indic prudent prefer make
repurchas time share look attract
valu marketplac howev recogn
edward share consist ran ahead intrins
valu opportun repurchas share attract
valuat far
million repurchas compani pay
dividend merger acquisit strategi also remain
research develop effort smaller acquisit
expand product offer
purchas
technolog edward ride high growth wave
transcathet aortic valv expect abl
easili fund growth support strateg acquisit
financi resourc cash flow unless
firm becom enamor
opportun someth view unlik
anticip major chang easili manag capit
base rel narrow concentr product
portfolio edward rate firm uncertainti
high volum edward heart valv still requir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
major surgeri implant medic industri
move toward minim invas procedur
cut recoveri time cost although edward
current enjoy duopoli transcathet aortic valv
 new competitor
horizon lotu edg devic easier
use faster use work broader rang patient
could cut sapien franchis recogn boston
prove fierc competitor cardiac
devic market clinic outcom sapien valv
much longer term yet assess durabl
product meet exceed track record
surgic valv clinician may wari use product
younger patient addit preliminari data
hint substanti portion elderli patient
popul would expir anyway independ
caus within sever year even implant
sapien valv rais question medicar
appetit reimburs expens devic put
pressur tavr manufactur demonstr
econom valu technolog edward much ride
tmtt
product -- area firm alreadi seem sever
pipelin product fail pan final edward could see
competit surgic tool busi minim
invas surgic system maker
enter cardiac surgeri market
success commerci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
michael mussallem ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund growth fund amer
capit research manag compani
new york mellon corp
share
fund
share
fund
think edward stewardship exemplari previous
group vice presid baxter michael mussallem
ceo chairman edward sinc spin-off
offer steadi presenc helm mussallem receiv
reason compens like goal
bonu place emphasi revenu growth free
cash flow growth net incom also taken
consider think often subject
would like see even greater detail specif
measur mussallem judg would prefer
see free cash flow gener weight heavili
net incom growth pleas edward reli
restricted-stock unit vest five year rather
stock option alon encourag mussallem
manag edward eye toward longer term
like succession-plan updat provid
board meet ensur board highli involv
survey manag talent potenti execut
posit think firm overal corpor govern
polici well design
corporate-alloc standpoint edward made
wise decis unlik larger rival edward
reli heavili serial acquisit instead
first prioriti plow resourc intern innov
kept surgic heart valv busi
leadership posit support consist
meaning innov transcathet aortic valv
portfolio one major earli acquisit edward made
percutan valv million
includ mileston payment laid
foundat edward sapien technolog addit
pvt catapult edward race enter tavr
market first edward might lucki
purchas mani early-stag technolog
end gutter ball nevertheless edward enjoy
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
strong posit categori project grow
billion edward recent acquisit cardiaq
harpoon valtech bolster firm invest
transcathet mitral valv therapi even though
commerci technolog could take year
think edward strong posit pursu market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
perform track along full-year
project havent made chang
estim boost fair valu
estim bake optimist estim
long-term growth cash flow realiz sinc last
updat see littl chang view edward narrow
econom moat howev think worth monitor
firm stabl moat trend next month
pivot trial transcathet mitral tricuspid
get closer fruition preliminari clinic data favor
european adopt pascal cardioband robust
pleas hear transcathet aortic sapien
valv sale seem grow line procedur growth
second quarter shift saw
last year appear aggress
price corevalv edward indic lost
market share remain disciplin premium
price quarterli sapien revenu sale
respect underli basi see
littl evid rival control
launch lotu edg tavr slow sapien growth
nonetheless wouldnt surpris see practition
tri lotu next quarter boston ramp
physician train establish center
boston roll-out
met
enthusiasm still take time put dent sapien
growth view lotu edg current indic
inoper high surgic risk patient sapien
alreadi expand indic includ intermedi
risk pool expect expans encompass
low surgic risk patient second half boston
meanwhil still enrol trial intermedi risk
item caught attent quarter first
launch pascal europ run smoothli
cardioband suppli improv two tmtt
product first edward gate european
adopt give us sens devic might
perform sale remain small million
second quarter expect acceler edward
cardiologist train new center establish
next month particularli interest pascal
consid rival abbott recent success mitraclip
saw growth second quarter edward
expect begin enrol pivot pascal trial
function mitral regurgit end year
market
though cardioband struggl manufactur
challeng constrain suppli edward
shift manufactur site improv
situat unlik pascal cardioband first
new direct annuloplasti devic enter market
demonstr strong eas use think could hold
potenti pascal could provid
durabl repair annulu especi function mitral
condit put particular stress anatomi mitral
earliest
discontinu self-expand centera tavr product
market europ stop develop
forma devic tricuspid diseas order focu
resourc pascal sapien mitral use
cardioband although medic technolog busi
often one enough shot goal seem
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
edward shot goal perhap exceed firm
bandwidth success develop commerci
way enviabl problem
nevertheless look favor manag decis
alloc resourc deliber support strongest
candid potenti underscor
make apolog make concentr bet
differenti superior technolog back
appropri resourc
fve apr
project top line gross margin slightli
exceed expect particularli
concern slower start anticip
adopt new product year goe translat
stronger growth come quarter hold
firm valuat overal edward remain strong
competit posit reiter firm narrow
moat rate continu develop portfolio
technolog begin
launch product europ may rethink
edward moat trend potenti upgrad posit
competit entranc boston
scientif abbott horizon edward focus
bestimprov innov
heart valv product firm plenti plate
roll sapien ultra introduct centera
pascal harpoon tmv transcathet mitral valv
repair europ on-going shift cardioband
manufactur edward site still view
competit pictur europ transcathet aortic valv
replac market instruct market
four competitor could reason play
respect edward leadership posit suspect
edward conced market share
particularli near term practition tri boston
lotu edg abbott portico howev longer
term dont expect portico abl garner
peripher posit product doesnt seem
perform better sapien corevalv boston lotu
may better carv nich posit well-
suit complex patient think practition
experi sapien strong clinic data support
leadership edward
recent data reveal american
colleg cardiolog confer march extrem
impress think data pave way tavr
becom standard care low-risk patient
expect indic expand includ
patient time year base saw
label expand includ intermediate-risk patient
indic creep necessarili translat new
bolu patient right away inclin see
new pool patient contribut steadi double-digit
growth tavr support project low-
mid-single-digit tavr growth edward
biggest question whether price declin
time thu far edward disciplin
price bolster grow bodi serious impress
clinic data sapien howev weve long contend
valu equat low-risk patient differ
inoper high-risk patient surgic
valv replac valv roughli one fifth
cost sapien legitim option thu weve bake
price declin keep eye
entranc two competitor could put
pressur price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
new tavr clinic data provid potenti
impress although necessarili surpris
favor clinic data support use
transcathet aortic valv low-risk patient reveal
late-break session annual american colleg
cardiolog meet edward
lifesci alreadi assum penetr
tavr product patient segment result
leav fair valu wide moat intact
howev plan rais fair valu narrow-moat
edward lifesci incorpor project
transcathet mitral tricuspid product
valuat emerg technolog
secur regulatori approv europ may also
consid turn edward moat trend posit make
progress develop commerci rang
consist data intermediate-risk patient tavr
least compar surgic valv replac among
low-risk popul medtron corevalv evolut
demonstr non-inferior surgeri think
pave way addit indic edward went
one step demonstr sapien superior
tradit surgic valv replac among low-risk
patient base rate death stroke
rehospit one year expect strength
latest sapien data translat substanti
penetr low-risk patient pool also think
data reinforc edward manag current strategi
hold price last year result
eros market share convers clinic result may
put price pressur seek protect
market share believ grow amount
consist favor clinic data edward could also
make difficult break
third place relaunch lotu year
surpris chang fair valu estim feb
gener line expect dont
anticip materi chang fair valu estim
make slight adjust beyond sale
transcathet aortic valv full year close
expect howev surgic heart valv fell short
estim off-set robust perform
critic care enjoy robust adopt next-
gener monitor platform adjust
legal settlement boston scientif
impair charg relat valtech acquisit
fourth-quart oper incom earn slightli
exceed project unfortun rival abbott
pursu edward intellectu properti litig
certain market earli tell relat
financi implic might could see unfold
next year remain confid edward narrow
econom moat clinic data associ
edward competit transcathet mitral valv
technolog begin dribbl time
period may consid turn edward moat trend
posit data favor firm continu
maintain lead develop technolog
although growth tavr sale moder edward
still expect expans patient pool support low-
double-digit growth anticip see
favor data trial share
cardiolog confer next month put edward
track low-risk indic year-end stick
expect low-single-digit growth surgic
valv like rais estim faster growth
critic care roughli million transcathet
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mitral valv sale though materi shift
final particularli worri tavr share
declin edward absorb stem
mainli firm decis stand premium
price manag estim sapien franchis lost
roughli basi point market share last year
perspect alarm addit
firm alreadi teed next-gen sapien ultra
receiv european regulatori approv late
base weve seen past new sapien
platform roll anticip posit recept
practition help edward eke back share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
